ReviewBiomedicines2026
The Diabetes Paradox in Aortic Aneurysms: An Unexpected Inverse Association.
Review in Biomedicines, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aortic aneurysms are associated with substantial morbidity and mortalitbecause of the risk of progressive dilation, rupture, and related acute aortic complications. Although diabetes mellitus (DM) is a major cardiovascular risk factor, epidemiological studies have consistently reported an inverse association between DM and the prevalence and progression of abdominal aortic aneurysm (AAA). More limited evidence suggests an inverse association between diabetes and thoracic aortic aneurysm. Accordingly, this review focuses primarily on AAA; where available, evidence concerning TAA and aortic dissection is discussed separately. This review examines the pathophysiological mechanisms underlying the inverse association between DM and aortic aneurysm development. Key mechanisms include the effects of hyperglycemia on extracellular matrix remodeling, particularly through modulation of matrix metalloproteinase (MMP-2 and MMP-9) activity, increased formation of advanced glycation end products (AGEs), and enhanced collagen cross-linking. Experimental and translational evidence suggests that diabetes may influence inflammatory cell states and mural neoangiogenesis, although these effects appear to be context- and model-dependent. Antidiabetic therapies, including metformin, DPP-4 inhibitors, GLP-1 receptor agonists, thiazolidinediones, sulfonylureas, and SGLT2 inhibitors, may also contribute to the observed association through glucose-lowering and/or pleiotropic vascular effects. Furthermore, diabetes-related changes in aortic wall biomechanics, including increased wall thickness and potentially altered wall stress, may contribute to aneurysm stabilization. Overall, DM is associated with a lower prevalence and slower progression of AAA, potentially through a combination of metabolic, inflammatory, structural, and treatment-related mechanisms. These observations should not be interpreted as evidence that diabetes or chronic hyperglycemia is clinically beneficial; rather, they may help identify biological pathways relevant to aneurysm development and progression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.